This randomized phase IIb trial studies how well low-dose carvedilol works in preventing
heart failure in cancer survivors exposed to high dose anthracyclines for management of
childhood cancer. Patients who received high-dose anthracycline chemotherapy are at a much
greater risk for developing heart failure compared to survivors who didn?t get any
anthracycline chemotherapy. Heart failure happens when the heart muscle has been weakened and
can?t pump blood as well as it should. Carvedilol may help lower the risk of cardiovascular
complications.
Intervention
Carvedilol, Laboratory Biomarker Analysis, Pharmacological Study, Quality-of-Life Assessment, Questionnaire Administration, Pharmacogenomic Study, Placebo Administration
Condition
Cancer Survivor
Investigators
Saro H Armenian